TGF-beta Ligand Design via Subdomain Segmentation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods face challenges in specifically modifying and generating significant quantities of Transforming Growth Factor-beta (TGF-β) ligands, which are essential for therapeutic applications due to their role in developmental and cellular processes.

Innovation Solution

The development of recombinant chimeric polypeptides composed of segments from parental TGF-beta proteins, specifically designed to modulate pathways associated with the TGF-beta family, such as the SMAD or DAXX pathway, by selecting and conjoining sequence segments to create novel ligands with unique properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional methods are used to modify TGF-β ligands, then the ability to specifically alter properties is limited, but the complexity of new methods required to achieve specific modification is increased

Engineering Contradiction:
Improveability to specifically modify and alter properties of TGF-β ligandsVSAvoidcomplexity of methods required for modification
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The TGF-β ligand is divided into six distinct subdomains (numbered 1-6) that can be independently manipulated. This segmentation allows specific regions to be modified while preserving overall structure and function, enabling targeted property alteration without requiring complete redesign of the ligand.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Different subdomains of the TGF-β ligand are assigned specific functional roles (e.g., receptor binding, dimerization, stability). By modifying only the relevant local subdomain rather than the entire ligand, specific properties can be altered while maintaining other critical functions, thus improving adaptability without proportionally increasing complexity.

Inventive Principle:
Principle #3Local quality

2Productivity

If natural TGF-β ligands are used for therapeutic applications, then biological activity is achieved, but the ability to generate significant quantities with desired properties is limited

Engineering Contradiction:
Improvequantity of TGF-β ligands that can be generatedVSAvoidtherapeutic efficacy and specific biological activity
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The six-subdomain framework provides a universal platform that can generate multiple different TGF-β ligand variants with distinct therapeutic properties. By combining different sequences in each subdomain position, a library of ligands with varied activities can be created from a single modular design, increasing productivity while maintaining reliability through structure-activity relationship understanding.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If the structural framework of TGF-β ligands is divided into six subdomains for modular design, then new ligands with unique properties can be created, but the complexity of designing and assembling these chimeric polypeptides increases

Engineering Contradiction:
Improvediversity of TGF-β ligand properties and activitiesVSAvoidcomplexity of constructing chimeric polypeptides
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The TGF-β ligand is divided into six distinct subdomains (numbered 1-6) that can be independently manipulated. This segmentation allows specific regions to be modified while preserving overall structure and function, enabling targeted property alteration without requiring complete redesign of the ligand.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Chimeric TGF-β ligands are constructed by merging sequence segments from different parental TGF-β ligands at defined subdomain boundaries. This modular combining approach allows systematic generation of diverse ligand variants while maintaining structural integrity and simplifying the design process through standardized assembly rules.

Inventive Principle:
Principle #5Merging (Combining)

Data Source

PatentEP2401293B1Designer ligands of TGF-beta superfamily
Publication Date: 2016.02.10 JOINT CENTER FOR BIOSCIENCES
  • EP2401293B1 patent drawingFigure 1A~1B
  • EP2401293B1 patent drawingFigure 2
  • EP2401293B1 patent drawingFigure 3

AI summary

The present disclosure relates to chimeric polypeptide having TGF- beta activity, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.